Based on the latest 2018Q3 regulatory filing with the SEC, Ledyard National Bank reduced its stake in Edwards Lifesciences Corp (EW) by 67.03%. 35,419 shares were sold by Ledyard National Bank as the company’s stock rose 13.75% while stock markets declined. At the end of 2018Q3, the institutional investor held 17,419 shares of the industrial specialties company, priced at $3.03 million, down from 52,838 at the end of the previous reported quarter. $36.09B is the market cap of Edwards Lifesciences Corp. EW is touching $173.71 during the last trading session, after increased 2.61%.Edwards Lifesciences Corporation is uptrending after having risen 37.86% since March 3, 2018. EW has 1.28 million volume or 2.38% up from normal. EW outperformed by 37.86% the S&P 500.

For a total of shares it increased its holding in by shares in the quarter, and has risen its stake in .

A couple more Edwards Lifesciences Corporation (NYSE:EW) news were brought out by: Globenewswire.com which released on February 12, 2019 “Bragar Eagel & Squire, PC is Investigating the Board of Directors of CAS Medical Systems, Inc. (CASM) on Behalf of Stockholders and Encourages CASM Investors to Contact the Firm – GlobeNewswire”, also Seekingalpha.com on February 19, 2019 brought out “Merger Arbitrage Mondays – February 18, 2019 – Seeking Alpha”, the next Seekingalpha.com is “Edwards’ Pascal valve cleared in Europe for mitral regurgitation – Seeking Alpha” on February 19, 2019. Globenewswire.com has article titled “Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth – GlobeNewswire”.

Edwards Lifesciences Corporation (NYSE:EW) Ratings Coverage

In total 10 analysts cover Edwards Lifesciences (NYSE:EW). “Buy” rating has 5, “Sell” are 2, while 3 are “Hold”. 50% are bullish. 15 are the (NYSE:EW)’s analyst reports since October 2, 2018 according to StockzIntelligence Inc. On Friday, December 7 Morgan Stanley maintained Edwards Lifesciences Corporation (NYSE:EW) with “Overweight” rating. On Tuesday, October 2 the firm has “Neutral” rating by Guggenheim given. On Wednesday, February 20 the stock has “Sell” rating by Barclays Capital. On Friday, January 18 the rating was upgraded by Bank of America to “Buy”. On Monday, February 25 Citigroup maintained Edwards Lifesciences Corporation (NYSE:EW) with “Sell” rating. On Monday, October 29 the rating was maintained by Citigroup with “Sell”. On Thursday, October 11 the company was maintained by Morgan Stanley. On Wednesday, January 2 the firm earned “Sell” rating by Citigroup. On Thursday, December 6 the firm earned “Outperform” rating by Raymond James. On Thursday, December 6 Jefferies maintained Edwards Lifesciences Corporation (NYSE:EW) with “Buy” rating.